News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PSI Announces Collaboration With Synta Pharmaceuticals for the GALAXY-2 Phase III Non-Small Cell Lung Cancer Trial



3/5/2013 9:45:37 AM

ZUG, Switzerland--(BUSINESS WIRE)--PSI CRO, a full-service contract research organization, announced today that the company has been selected by Synta Pharmaceuticals to conduct their GALAXY-2 trial, a Randomized Phase III Study of Ganetespib in Combination with Docetaxel versus Docetaxel Alone in Patients with Advanced Non-Small-Cell Lung Cancer. PSI is currently initiating this 500-patient study across 15+ countries. PSI has been conducting clinical trials in oncology since 1994. Lung cancer represents one of the central oncological indications in the PSI portfolio. PSI’s commitment to thorough feasibility and “go-the-extra-mile“ project management, has secured PSI’s reputation for high quality and on-time delivery in the area of lung cancer.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES